Proteomics‑based prognostic signature predicts prognosis and immunity in glioma

Abstract

The prognosis of glioma patients is closely associated with the expression of immune cells and oncoproteins. Therefore, protein-related signatures were conducted to improve the prediction of overall survival (OS) in glioma patients after surgery. Differential oncoproteins were selected from the Renji cohort and The Cancer Genome Atlas (TCGA) database. The least absolute shrinkage and selection operator (LASSO) regression model is designed to construct the multiple oncoprotein model related to OS in two test series. Furthermore, the 6-oncoprotein model was tight associated with immune cell infiltration, immune function, and immunotherapy. In summary, the 6-oncoprotein marker, a favorable biomarker for the prognosis and immune characteristics of glioma, could help individualized immunotherapy for patients with glioma.